LGND
VENTE TOTALE: 7 138 titres (~2 090 062,08 $ US)
- Insiders
- Haas Jason
- Total bought
- —
- Total sold
- $2,090,062
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-09-06
LGND combines exceptional financial health (liquidity score 95, fundamentals trend 85) with a moderately strong earnings catalyst (score 60, confidence 0.65), driven by higher royalty revenues and the transformative…
The first sentence of the analysis written for LGND on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.5% | 93.4% | 73.3% | 73.1% | 74.3% | |
| Ebit Margin | 59.3% | 3.3% | 49.0% | 19.3% | 38.0% | |
| Ebitda Margin | 71.9% | 24.4% | 76.8% | 41.4% | 59.1% | |
| Operating Profit Margin | 17.6% | -13.5% | 9.1% | 1.5% | 43.0% | |
| Pretax Profit Margin | 59.3% | 1.5% | 48.5% | 18.4% | 29.9% | |
| Continuous Operations Profit Margin | 46.4% | -2.4% | 41.0% | -2.7% | 31.6% | |
| Net Profit Margin | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | |
| Bottom Line Profit Margin | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | |
| Current Ratio | 22.225 | 8.934 | 14.148 | 2.668 | 11.154 | |
| Quick Ratio | 21.982 | 8.554 | 12.720 | 2.533 | 10.499 | |
| Solvency Ratio | 0.291 | 0.280 | 1.027 | 0.061 | 0.227 | |
| Cash Ratio | 4.671 | 1.948 | 1.368 | 0.455 | 0.469 | |
| Price To Earnings Ratio | 29.359 | -487.045 | 23.649 | -33.737 | 27.850 | |
| Price To Earnings Growth Ratio | -0.010 | 4.540 | -0.094 | 0.215 | -0.014 | |
| Forward Price To Earnings Growth Ratio | -0.010 | 4.540 | -0.094 | 0.215 | -0.014 | |
| Price To Earnings Diluted Ratio | 30.843 | -487.045 | 24.293 | -33.737 | 28.850 | |
| Price To Earnings Diluted Growth Ratio | -0.011 | 4.531 | -0.098 | 0.212 | -0.015 | |
| Price To Book Ratio | 3.594 | 2.360 | 1.763 | 1.886 | 1.951 | |
| Price To Sales Ratio | 13.638 | 11.726 | 9.408 | 5.742 | 6.634 | |
| Price To Free Cash Flow Ratio | 74.759 | 25.318 | -289.191 | 9.396 | 22.880 | |
| Price To Operating Cash Flow Ratio | 74.074 | 20.194 | 24.919 | 8.174 | 20.336 | |
| Debt To Assets Ratio | 0.289 | 0.008 | 0.008 | 0.115 | 0.250 | |
| Debt To Equity Ratio | 0.444 | 0.009 | 0.009 | 0.147 | 0.395 | |
| Debt To Capital Ratio | 0.307 | 0.008 | 0.009 | 0.128 | 0.283 | |
| Long Term Debt To Capital Ratio | 0.305 | 0.000 | 0.000 | 0.000 | 0.281 | |
| Financial Leverage Ratio | 1.534 | 1.134 | 1.123 | 1.276 | 1.580 | |
| Working Capital Turnover Ratio | 0.492 | 0.649 | 0.681 | 0.668 | 0.587 | |
| Operating Cash Flow Ratio | 1.318 | 2.615 | 2.954 | 1.395 | 1.891 | |
| Operating Cash Flow Sales Ratio | 0.184 | 0.581 | 0.378 | 0.702 | 0.326 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.991 | 0.798 | -0.086 | 0.870 | 0.889 | |
| Debt Service Coverage Ratio | 33.558 | 11.276 | 138.713 | 0.509 | 7.489 | |
| Interest Coverage Ratio | 10.010 | -7.444 | 18.204 | 1.688 | 5.293 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 1.797 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.109 | 13.659 | 8.042 | 1.571 | 0.243 | |
| Capital Expenditure Coverage Ratio | 109.201 | 4.941 | 0.921 | 7.691 | 8.994 | |
| Dividend Paid And Capex Coverage Ratio | 109.201 | 4.941 | 0.921 | 7.691 | 8.994 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 20.405 | 46.442 | 12.085 | 14.402 | 13.359 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.5% | ▲4.2% | ▲15.2% |
| Ebit Margin | 59.3% | ▲56.0% | ▲25.5% |
| Ebitda Margin | 71.9% | ▲47.5% | ▲17.2% |
| Operating Profit Margin | 17.6% | ▲31.1% | ▲6.1% |
| Pretax Profit Margin | 59.3% | ▲57.8% | ▲27.8% |
| Continuous Operations Profit Margin | 46.4% | ▲48.8% | ▲23.6% |
| Net Profit Margin | 46.4% | ▲48.8% | ▲28.3% |
| Bottom Line Profit Margin | 46.4% | ▲48.8% | ▲28.3% |
| Current Ratio | 22.225 | ▲13.291 | ▲10.399 |
| Quick Ratio | 21.982 | ▲13.428 | ▲10.724 |
| Solvency Ratio | 0.291 | ▲0.011 | ▼-0.086 |
| Cash Ratio | 4.671 | ▲2.723 | ▲2.889 |
| Price To Earnings Ratio | 29.359 | ▲516.404 | ▲117.344 |
| Price To Earnings Growth Ratio | -0.010 | ▼-4.549 | ▼-0.937 |
| Forward Price To Earnings Growth Ratio | -0.010 | ▼-4.549 | ▼-0.937 |
| Price To Earnings Diluted Ratio | 30.843 | ▲517.889 | ▲118.203 |
| Price To Earnings Diluted Growth Ratio | -0.011 | ▼-4.542 | ▼-0.935 |
| Price To Book Ratio | 3.594 | ▲1.234 | ▲1.284 |
| Price To Sales Ratio | 13.638 | ▲1.912 | ▲4.209 |
| Price To Free Cash Flow Ratio | 74.759 | ▲49.441 | ▲106.127 |
| Price To Operating Cash Flow Ratio | 74.074 | ▲53.880 | ▲44.535 |
| Debt To Assets Ratio | 0.289 | ▲0.282 | ▲0.155 |
| Debt To Equity Ratio | 0.444 | ▲0.435 | ▲0.243 |
| Debt To Capital Ratio | 0.307 | ▲0.299 | ▲0.160 |
| Long Term Debt To Capital Ratio | 0.305 | ▲0.305 | ▲0.188 |
| Financial Leverage Ratio | 1.534 | ▲0.400 | ▲0.205 |
| Working Capital Turnover Ratio | 0.492 | ▼-0.157 | ▼-0.123 |
| Operating Cash Flow Ratio | 1.318 | ▼-1.297 | ▼-0.717 |
| Operating Cash Flow Sales Ratio | 0.184 | ▼-0.397 | ▼-0.250 |
| Free Cash Flow Operating Cash Flow Ratio | 0.991 | ▲0.193 | ▲0.299 |
| Debt Service Coverage Ratio | 33.558 | ▲22.283 | ▼-4.751 |
| Interest Coverage Ratio | 10.010 | ▲17.454 | ▲4.460 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▼-0.359 |
| Operating Cash Flow Coverage Ratio | 0.109 | ▼-13.550 | ▼-4.615 |
| Capital Expenditure Coverage Ratio | 109.201 | ▲104.260 | ▲82.852 |
| Dividend Paid And Capex Coverage Ratio | 109.201 | ▲104.260 | ▲82.852 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 20.405 | ▼-26.037 | ▼-0.934 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.66B | $1.96B | $1.24B | $1.13B | $1.60B | |
| Enterprise value | $3.93B | $1.89B | $1.22B | $1.17B | $1.91B | |
| EV / Sales | 14.67x | 11.34x | 9.28x | 5.96x | 7.90x | |
| EV / Op. cash flow | 79.68x | 19.52x | 24.58x | 8.48x | 24.20x | |
| EV / Free cash flow | 80.41x | 24.48x | -285.26x | 9.75x | 27.23x | |
| EV / EBITDA | 20.41x | 46.44x | 12.09x | 14.40x | 13.36x | |
| Net debt / EBITDA | 1.44x | -1.60x | -0.17x | 0.53x | 2.13x | |
| Current ratio | 22.23x | 8.93x | 14.15x | 2.67x | 11.15x | |
| Income quality | 0.40x | -24.07x | 0.95x | -4.13x | 1.38x | |
| Graham number | $87 | — | $52 | — | $62 | |
| Graham net-net | $12 | $10 | $7 | $5 | -$3 | |
| Tax burden | 78.3% | -160.1% | 81.9% | -92.6% | 79.1% | |
| Interest burden | 100.0% | 45.3% | 99.0% | 95.2% | 78.6% | |
| Working capital | $794.8M | $294.4M | $220.6M | $164.8M | $423.1M | |
| Invested capital | $1.33B | $691.2M | $648.7M | $650.6M | $948.2M | |
| Return on assets | 8.0% | -0.4% | 6.6% | -4.4% | 4.4% | |
| Operating ROA | 3.8% | -2.6% | 1.5% | 0.3% | 7.8% | |
| Return on tangible assets | 12.0% | -0.7% | 13.6% | -11.0% | 7.1% | |
| Return on equity | 12.2% | -0.5% | 7.4% | -5.6% | 7.0% | |
| Return on invested capital | 2.4% | 4.0% | 1.3% | -0.1% | 8.3% | |
| Return on capital employed | 3.1% | -2.5% | 1.6% | 0.5% | 8.3% | |
| Earnings yield | 3.4% | -0.2% | 4.2% | -3.0% | 3.6% | |
| Free cash flow yield | 1.3% | 3.9% | -0.3% | 10.6% | 4.4% | |
| Capex / Op. cash flow | 0.9% | 20.2% | 108.6% | 13.0% | 11.1% | |
| Capex / Depreciation | 1.3% | 55.7% | 147.4% | 34.9% | 17.2% | |
| Capex / Sales | 0.2% | 11.8% | 41.0% | 9.1% | 3.6% | |
| SG&A / Sales | 34.5% | 47.1% | 40.2% | 35.7% | 19.4% | |
| R&D / Sales | 30.3% | 12.8% | 18.7% | 18.4% | 13.3% | |
| Stock comp / Sales | 0.0% | 24.6% | 19.6% | 30.7% | 16.1% | |
| Intangibles / Total assets | 33.6% | 39.5% | 51.2% | 60.1% | 38.0% | |
| Days sales outstanding | 83d | 93d | 109d | 65d | 138d | |
| Days payables outstanding | 179d | 172d | 25d | 37d | 49d | |
| Operating cycle | 589d | 558d | 359d | 157d | 299d | |
| Cash conversion cycle | 409d | 385d | 334d | 120d | 250d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+86.6%EV / Sales ▲+29.4%EV / EBITDA ▼-56.1%EV / Op. cash flow ▲+60.155Earnings yield ▲+0.036
Profitability
Return on equity ▲+0.127Return on assets ▲+0.084Return on invested capital ▼-0.016Return on capital employed ▲+0.056Operating ROA ▲+0.064Income quality ▲+24.466Tax burden ▲+2.384
Efficiency
Days sales outstanding ▼-9.589Days payables outstanding ▲+6.931Operating cycle ▲+30.866Cash conversion cycle ▲+23.935Capex / Sales ▼-0.116R&D / Sales ▲+0.175
Balance-sheet strength
Current ratio ▲+13.291Net debt / EBITDA ▲+3.033Working capital ▲+500377000.000Invested capital ▲+638323000.000Intangibles / Total assets ▼-0.059
Change over 5 years
Valuation
Market cap ▲+128.2%EV / Sales ▲+85.8%EV / EBITDA ▲+52.7%EV / Op. cash flow ▲+55.472Earnings yield ▼-0.002Graham number ▲+25.491
Profitability
Return on equity ▲+0.053Return on assets ▲+0.036Return on invested capital ▼-0.058Return on capital employed ▼-0.052Operating ROA ▼-0.040Income quality ▼-0.982Tax burden ▼-0.008
Efficiency
Days sales outstanding ▼-55.372Days payables outstanding ▲+130.082Operating cycle ▲+289.866Cash conversion cycle ▲+159.784Capex / Sales ▼-0.035R&D / Sales ▲+0.170
Balance-sheet strength
Current ratio ▲+11.071Net debt / EBITDA ▼-0.700Working capital ▲+371738000.000Invested capital ▲+381312000.000Intangibles / Total assets ▼-0.044
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-15 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-10-22 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2020-04-03 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
| 2020-04-03 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-16 Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,358 shares of the biotechnology company''s stock after purchasing an additional 1,900 shares during the quarter.
- 2026-08-06 Ligand Pharmaceuticals Q2 Earnings Call Highlights Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.
- 2026-08-06 Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
- 2026-08-05 Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership Arrowstreet Capital Limited Partnership reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 27.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,564 shares of the biotechnology company''s stock after selling 5,472 shares during the period.
- 2026-07-28 Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND Ashford Capital Management Inc. reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 207,565 shares of the biotechnology company''s stock after selling 6,213 shares during the quarter. Ligand Pharmaceuticals makes
- 2026-07-23 Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026.
- 2026-07-21 Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.
- 2026-07-14 Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.
- 2026-07-14 XOMA Royalty Announces Closing of Its Acquisition by Ligand EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.
- 2026-07-12 5 Stock Setups Where Wall Street Sees the Most Upside Right Now The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now